Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6379MR)

This product GTTS-WQ6379MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ6379MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13279MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ15681MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ11682MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ1870MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ10495MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ9351MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ5100MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ1317MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW